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Abstract
Background: Depression and anxiety are prevalent mental disorders among the working population with potentially
high personal and financial cost. The overall aim of this study was to test the applicability of an outreach collaborative
model for early identification and treatment of clinical and sub-clinical mental disorders among Danish employees. This
applicability was examined by I) investigating the fractions of identified and treated clinical and subclinical cases, II)
describing the distribution and characteristics of cases identified and III) investigating the effect of allocated treatment.
Methods: A longitudinal study design with four assessments (T0-T3) over 16months was applied. Self-reporting
questionnaires probing for psychopathology were distributed to all employees in six consecutively enrolled companies
at the four time points. Employees meeting the screening criteria at T1 were assessed diagnostically. Subjects diagnosed
with a clinical mental disorder were allocated to outpatient psychiatric treatment, and subjects with subclinical conditions
were allocated to preventive cognitive behavioural therapy. Follow-up was conducted 6 and 12months after initiation of
treatment. We used chi-squared test and F-test to compare the different groups on baseline characteristics and mixed
effects linear regression to analyse the treatment effects.
Results: Forty (6.8%) of the 586 responders at T1 were diagnosed with a clinical mental disorder and referred to
outpatient psychiatric treatment. Thirty-three (5.6%) were affected by a subclinical condition and referred to preventive
treatment. Nearly two-thirds (63%) of the employees diagnosed with a clinical condition had never received treatment
before. Symptom severity decreased significantly for both treated groups until follow-up. When compared to a
composed control group, subclinical cases displayed a more rapid initial significant symptomatic decrease on the global
symptom scale (coefs = − 0.914, 95% CI [− 1.754, − 0,075]) and anxiety sub-scale (coefs =− 1.043, 95% CI [− 2.021, − 0.066]).
This did not apply to the clinical cases as no significant difference in change were identified.
Conclusions: The outreach collaborative model demonstrated an applicability to identify both clinical and subclinical
cases, among these a high number of employees with an unmet need for treatment. We found evidence of a positive
initial effect on symptomatology from the allocated preventive treatment among the subclinical cases, but not for clinical
cases.
Trial registration: Retrospectively registered at December 18, 2018 at clinicaltrials.gov, identifier: NCT03786328.
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Background
Depression and anxiety are the most prevalent mental dis-
orders among the working population [1–3]. The condi-
tions have potentially high personal and financial costs
given their association with long-term and recurrent sick-
ness absence, at-work performance deficit, early retirement,
decreased social function, low job satisfaction and impaired
quality of life [2, 4–11]. The total cost of work-related de-
pression in the European Union was estimated to approxi-
mately €620 billion in 1 year covering productivity loss,
treatment costs and disability benefit payments [12, 13].
In addition to clinical conditions, many employees are
affected by symptoms of depression and anxiety at a
subclinical level which may be socially inhibiting for the
individual as well as negatively impacting job satisfac-
tion, work productivity and attendance [1, 10, 14]. Un-
treated and not early identified, these subclinical cases
can lead to actual mental disorder [15, 16].
In both the general population and the working popu-
lation, evidence has demonstrated a high level of unmet
need for mental health care and treatment [17–19]. The
unmet needs are partly explained by diagnostic difficul-
ties and inadequate treatment in general practice, and
partly by the fact that many individuals affected do not
seek professional help [20, 21].
In light of the high costs and unmet need for treat-
ment, prevention and early detection of mental disorders
among the working population ought to be a public
health priority [22]. Evidence suggests that much could
be gained by investing in preventive initiatives [12, 23].
Research studies within occupational mental health have
mainly tested workplace-initiated stress management
programmes or other universal prevention programmes
using work-related outcome measures like sickness ab-
sence, work productivity and cost-effectiveness [22, 24].
Secondary prevention and early intervention programmes
targeting mental health problems directly by using clinical
standardised measures of depression or anxiety are lim-
ited, or suffer from limitations such as weak control con-
ditions, short-term follow-up and lack of diagnostic
assessment [22, 25–27]. A valid study by Wang et al. [28]
tested a two-stage screening and outreach care manage-
ment programme among American workers with clinical
depression in a randomized controlled trial. Employees re-
ceiving the intervention improved significantly on both
clinical and job-related outcomes at 12-month follow-up
compared to employees receiving usual care. Thus, this
study points at a positive return of investment from out-
reach and enhanced treatment programmes. However, only
employees with symptom severity corresponding to at least
a moderate depression were eligible for randomization.
When targeting workplace mental health problems, it is
recommended to apply a collaborative approach between
workplaces and mental health specialists in order to
minimize the risk of misclassification and inadequate
treatment [25, 29].
For this study, we therefore developed an outreach
secondary prevention model to be tested in collaboration
between the psychiatric treatment system and work-
places in the North Denmark Region.
The overall aim of the study was to investigate the ap-
plicability of an outreach collaborative model for early
identification and treatment of clinical and sub-clinical
cases of mental disorder among a Danish working popu-
lation. The investigation had the following objectives:
I) To investigate the applicability of the early
identification model, measured as fractions of
identified clinical and subclinical cases, fraction of
cases who accepted treatment and fraction of cases
who completed treatment
II) To describe the distribution and characteristic of
clinical and subclinical cases identified by the early
identification model
III) To investigate the effect of allocated treatment on
symptomatology for clinical and subclinical cases
Methods
Study design
The study applied a longitudinal naturalistic design with
four points of assessment (T0-T3) during a period of 16
months for each participating company. The time from
T0 to T1 (4months) constituted a pre-treatment period
and was incorporated in the design as a control period for
comparison. After the second assessment (T1), screening
and diagnostic assessment were initiated. Identified cases
were afterwards allocated to treatment. Follow-up assess-
ments were conducted after 6months (T2) and 12months
(T3) for all employees. The longitudinal study design and
the four assessments are illustrated in Fig. 1. The assess-
ments used self-reporting questionnaires probing for
psychopathology. All questionnaires were mailed to the
employees’ private postal addresses at the four points of
assessment (T0-T3) followed by a reminder after 2 weeks
in case of no response.
Participants
In order to demonstrate the model’s applicability in a rep-
resentative sample, we decided to enrol six medium-large
companies with a minimum of 100 employees each.
Companies with more than 300 employees were not ad-
dressed due to the limitations of the available treatment
capacity. After approaching 24 companies from diverse
fields within both the public and private sector, six
companies agreed to participate. These companies were
consecutively enrolled from June 2007 to August 2013.
The primary reasons for declining participation were lack
of resources or time.
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Measures
The questionnaires used the Symptom Check List 90
Revised (SCL90-R) [30] as basis for identification of clin-
ical and subclinical cases of mental disorders and
follow-up to treatment. Questionnaires also collected
data on demography, different work-related characteris-
tics and job-satisfaction.
The SCL-90-R is a psychiatric self-report inventory
with high reliability and validity to measure overall psy-
chological distress and to detect changes [31–33]. In
each of the 90 scale items, the responders are to assess
the presence of a specific symptom on a 5-point Likert
scale from 0 = “not at all” to 4 = “very much”. The quo-
tient of the 90 items expresses the overall level of psy-
chological distress, referred to as the Global Severity
Index (GSI). The GSI-score ranges from 0 to 4 and the
higher the score, the higher the level of psychological
distress. The instrument also comprises nine subscales,
including the depression (DEP) and the anxiety (ANX)
subscales that have been established as being suitable in-
struments for proxies of depression and anxiety [34].
The mean GSI-level in the Danish general population
has been set to 0.45 (SD: 0.43) [14], and in outpatient
populations to range from 1.16 (SD: 0.49) to 1.70 (SD:
0.47) [35]. No Danish studies have published data on
average distress levels for subclinical samples. A Swiss
study reports mean GSI-levels for subclinical depression
of 0.64 and subclinical anxiety of 0.63 [36], and German
studies report mean GSI-level for primary care popula-
tions from 0.57 (SD: 0.49) to 0.89 (SD: 0.55) [37–39].
Rooted in the above GSI-levels, combined with the
recommendations from the SCL90-R manual, we applied
the following screening criteria for identification of clin-
ical and subclinical cases of mental disorder [1, 30–32]:
i) GSI score ≥ 0.63 or
ii) values of ≥0.63 in two or more subscales or
iii) values of ≥0.63 in the DEP subscale
The following criteria were based on raw-scores of the
SCL90-R.
Procedure
Participants meeting the screening criteria at the second
assessment (T1) were invited to a diagnostic assessment
in order to determine the presence of a mental disorder.
The diagnostic interviews were conducted by medical
doctors in Aalborg Psychiatric Hospital, all trained and ex-
perienced users of the diagnostic instruments utilized.
The presence of a mental disorder was initially determined
by use of Present State Examination (PSE) [40]. Partici-
pants assessed with a state of anxiety or depression were
afterwards rated on the Hamilton Depression Scale
(HAM-D) [41] and/or Hamilton Anxiety Scale (HAM-A)
to assess the severity of the condition [42]. Depending on
the outcome of the diagnostic interview, participants were
offered two different courses of treatment:
Treatment course I: Psychiatric treatment for clinical cases
Individuals diagnosed with a mental disorder according
to the PSE, and with HAM-D score ≥ 18 or HAM-A
score ≥ 20, were referred to psychiatric treatment in an
outpatient specialized clinic for affective disorders in
Aalborg Psychiatric Hospital. The treatment followed
standard treatment procedures for psychiatric outpa-
tients with diagnoses of depression and anxiety. Treat-
ment was performed by trained clinicians (psychiatrists,
psychologists and nurses) employed at the Clinic for
Affective Disorders. The course of treatment included
medical consultations as well as psychotherapeutic ses-
sions and continued until remission was achieved.
Treatment course II: Preventive treatment for subclinical
cases
Individuals assessed with subclinical conditions of de-
pression or anxiety, defined as a HAM-D score of 13–17
or a HAM-A score of 15–19, were offered preventive
treatment. This course of treatment consisted of eight
sessions of cognitive behavioural therapy (CBT) con-
ducted by clinical psychologists at Aalborg Psychiatric
Hospital. During the sessions, the therapeutic focus was
on stress-reduction and resilience.
Pre-treatment Treatment and Follow-up Treatment and Follow-up
period period period
0
Questionnaire
T0
Month
4 10 16
T1 T2 T3
Fig. 1 Study time line
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Statistical analysis
Initially, the primary analysis was carried out by count-
ing the number of clinical and subclinical cases identi-
fied from the early identification procedure, as well as
number of cases who accepted treatment and number of
cases who completed treatment.
Secondly, we performed a descriptive analysis with the
study population allocated into four groups: clinical
cases, subclinical cases, untreated cases and healthy sub-
jects. The group of untreated cases consisted of em-
ployees, who were allocated to treatment but declined
the treatment offer. The group of healthy subjects con-
sisted of all other responders, including employees with
scores below cut-off point, as well as employees above
cut-off points who turned out ‘false positives’ when
assessed diagnostically.
The groups were compared at baseline (T1) on demog-
raphy, work-related characteristics and the three outcome
measures GSI, DEP and ANX. Ordinal variables were
compared using chi-squared tests, and variables of con-
tinuous nature were compared using F-tests. Additionally,
the same comparisons were performed between treated
participants who completed the follow-up at T3 with par-
ticipants who did not.
To analyse the effect of both treatments, we used
mixed effects linear regression using random intercept
and with participants nested inside the companies.
The outcome measures were included separately as
dependent variables, while the time variable (mea-
sured in years), gender, age at baseline as well as a
group variable were added as covariates.
The regression analysis compared clinical and sub-
clinical cases during the follow-up period (T1-T3)
with a composed control group consisting of two sub-
groups. The first subgroup consisted of the untreated
cases, and the second subgroup included the treated
cases pre-diagnostically (T0-T1). Hence, point of
origin was specified to T1 for the first subgroup and
T0 for the second subgroup. To reduce the effects of
regression to the mean, cases in the latter subgroup
were excluded if not meeting the screening criteria at
T0.
A second order time covariate was added in the re-
gression as well as an interaction term for each of the
first and second order time variables, since the differ-
ences of the initial slopes and difference in change of
slopes between the groups were of interest. To investi-
gate the effects of seasonal variations, the regressions
were conducted twice with and without a variable indi-
cating in which quarter the participant entered the
period under investigation. Quantile-quantile plots were
used for visual inspection of the normality assumptions.
A p-value < 0.05 was considered statistically signifi-
cant. All analyses were carried out in Stata 13 [43].
Ethics
Information about the study was first provided to the work-
place management and the health and safety representatives
and subsequently to all employees at joint open meetings.
It was emphasised that the study was voluntary at all
levels. Written participant information accompanied
each questionnaire. The return of the questionnaires was
considered as acceptance of participation in the ques-
tionnaire part. Written informed consent was obtained
from all participants involved in diagnostic interview
and treatment. The employees were guaranteed
complete anonymity in relation to their workplace and
company management. The study was approved by the
Danish Data Protection Agency (j. 2008-58-0028). The
study was presented to the Danish Scientific Ethics
Committee (N-20070016), but the need for approval was
waived due to the nature of the study.
Results
Questionnaire response
Three public and three private corporations with an aver-
age number of 178 employees (range 130–240) at the time
of inclusion were enrolled. All individuals employed at
each point of time received the questionnaires. The ques-
tionnaire population were, therefore, slightly different at
each time-point, due to staff turnover.
At baseline (T1), a total of 586 (54.9%) employees of the
study population (n = 1068) returned the questionnaire and
were assessed according to the screening criteria. Non-re-
sponders thereby comprised 482 employees (45.1%). There
was a higher proportion of women among the responders
(41.1%) than among non-responders (31.7%) at baseline.
The average age for the responders were 45 years (min: 21,
max: 67). Response rates were higher than non-response
rates in company 1, 2 and 3 (above 50%), and lower in com-
pany 4, 5 and 6 (below 50%).
All response rates for each company at the four time
points are listed in Table 1.
Identified cases
Altogether 160 individuals met the screening criteria
and were invited to a diagnostic assessment and 130
accepted the invitation. Based on the diagnostic assess-
ment with the PSE, 73 were classified with either a clin-
ical or subclinical condition of mental disorder and
assigned to either psychiatric treatment (n = 40) or pre-
ventive treatment (n = 33). Fifteen declined the treat-
ment offer or did not receive treatment as part of the
study, either due to other available treatment options,
spontaneous recovery or non-attendance. Thus, 38 indi-
viduals classified with a clinical mental disorder received
psychiatric standard treatment with a mean treatment
period of 369 days (sd = 314; min = 52, max = 1162), and
20 individuals identified with a subclinical condition
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received preventive CBT treatment with a mean treat-
ment period of 103 days (sd = 81; min = 31, max = 343).
The cases identified correspond to a prevalence of
6.8% for a clinical condition of mental disorder, and
5.6% for a subclinical condition.
Figure 2 illustrates the procedure of the identification
of clinical and subclinical cases.
Baseline characteristics
Baseline characteristics for the clinical, subclinical and
untreated cases as well as healthy subjects are listed in
Table 2. We observed a statistically significant higher
proportion of women in the case groups than among
healthy subjects. Moreover, number of sick days during
the latest month, presence of physical illness and treat-
ment with psychotropic drugs were significantly higher
among all case groups than among healthy subjects.
Job-satisfaction was significantly lower in all case groups
than among healthy subjects.
No statistically significant differences on baseline char-
acteristics were found when comparing responders with
non-responders at follow-up.
Unmet need for treatment
Of the 40 employees identified with a clinical mental
condition, 33 were diagnosed with a depressive disorder,
1 with bipolar affective disorder, 1 with anxiety disorder,
2 with adjustment disorder and 1 with personality dis-
order. The remaining 2 individuals were not definitively
diagnosed as they rejected the treatment offer. Prior to
the initiation of treatment, only 14 (35.0%) of the 40 in-
dividuals identified with a clinical mental condition had
received treatment before (anti-depressive medication
and/or psychological treatment). Thus, 26 (65.0%) had
never pursued or received any treatment earlier in life,
corresponding to a prevalence of 4.1% of the study sam-
ple. Seven (21.2%) of the employees identified with a
subclinical condition had previously received treatment
for their mental health problems, and 23 (69.7%) had
never pursued or received treatment, corresponding to a
prevalence of 3.9% of the study sample.
Treatment effect
In Table 3, the symptom scores (GSI, DEP and ANX) at
the four measurement points are listed for all groups.
Scores decreased statistically significant from initiation
of treatment (T1) to 12-month follow-up (T3) for all
treated participants regardless of treatment, with the ex-
ception of the DEP-subscale for subclinical cases merely
demonstrating a trend-significant change. Untreated
cases also demonstrated a statistically significant reduc-
tion on the GSI and ANX scores. No significant reduc-
tion in symptom severity for healthy subjects was
observed.
There was a notable amount of missing responses in
all groups at 12-month follow-up, n = 10 (26.3%) among
clinical cases, n = 8 (40.0%) among subclinical cases, n =
6 (40.0%) among un-treated cases and n = 142 (27.7%)
among healthy subjects.
There were no statistically significant differences on
outcome measures at baseline when comparing re-
sponders with non-responders at follow-up.
In Table 4, the results from the main regression ana-
lysis including seasonal variations are displayed. Here,
we compared the difference in change over time
between the treated case groups and the control group
by investigating initial decline and overall change of
slopes. No significant difference in change was detected
in any outcome measures for clinical cases. For subclin-
ical cases, the initial slope and the change of slope
differed statistically on the GSI and ANX scales, but not
on the DEP-scale.
Discussion
The study investigated the applicability of an outreach
collaborative model for early identification and treat-
ment of clinical and subclinical conditions of mental
disorder among a sample of Danish employees. The
Table 1 Response rates for all companies at all time points (T0-T3)
Company Recipients
N
Response
N (%)
Recipients
N
Response
N (%)
Recipients
N
Response
N (%)
Recipients
N
Response
N (%)
T0: pre-treatment
assessment
T1: Screening, diagnostic
assessment and initiation
of treatment
T2: 6-month follow-up T3: 12-month follow-up
1. Public service 163 107 (65.6) 167 101 (60.5) 170 96 (56.5) 180 100 (55.6)
2. Public service 166 100 (60.2) 167 94 (56.3) 170 106 (62.4) 160 97 (60.6)
3. Private, financial 251 181 (72.1) 240 161 (67.1) 247 161 (65.2) 246 166 (67.5)
4. Private, manufacturing 148 74 (50.0) 162 71 (43.8) 165 71 (43.0) 156 69 (44.2)
5. Private, manufacturing 125 59 (47.2) 130 55 (42.3) 135 50 (37.0) 139 59 (42.4)
6. Public, education 198 88 (44.4) 202 92 (45.5) 185 82 (44.3) 182 72 (39.6)
Total 1051 609 (57.9) 1068 586 (54.9) 1072 566 (52.8) 1063 563 (53.0)
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model identified prevalence’s for clinical and subclinical
disorders similar to other studies and found evidence
pointing at a noticeable effect of early treatment for sub-
clinical cases measured on overall psychopathology. An
unpredicted finding was, however, the identification of a
high amount of unmet need for treatment for both
subclinical and clinical cases. Approximately 2/3 of the
employees diagnosed with a clinical diagnosis had never
received treatment for their mental health problems
before.
Previous studies found that half of the individuals with
treatment needs were untreated or received inadequate
treatment [18, 44]. Our study detects a considerable
higher proportion of unmet need for treatment, which
points at a pronounced need for initiatives for early de-
tection and treatment.
The prevalence estimates for clinical and subclinical
cases of mental disorder identified in this study
correspond with earlier findings in working populations
[1–3, 14]. The reliability of these prevalence estimates is
enhanced by the fact that all subjects meeting the
screening criteria were assessed diagnostically by
well-trained psychiatrists. However, there was a large
proportion of non-responders, which might have biased
our prevalence estimates.
In regard to treatment effect, we observed a statisti-
cally significant improvement in symptom severity
among both clinical and subclinical cases, equivalent to
the decline in depressive symptoms over a 12-month
period in the study by Wang et al. [28]. The untreated
cases also demonstrated a significant reduction in symp-
tom severity. The reason for this is unknown, but it
could be an effect of regression to the mean. However,
we are aware that some of these cases declined the study
offer for treatment due to other available treatment
options.
When comparing the symptomatic changes for the
treated groups with a composed control group, the treat-
ment effect were less evident. Among the clinical cases,
the symptomatic changes followed nearly the same
course as controls. Subclinical cases displayed a more
rapid initial decline in symptoms compared to controls.
A possible explanation might be that subclinical cases
were identified at a point of time where their mental
health problems were still of minor severity. Therefore,
they probably responded more rapidly to treatment than
clinical cases, which entered treatment in a more severe
mental health state. The rapid decline was, however,
equalized and transformed to a minor relative growth
after 6 months. The effect of the preventive treatment
Questionnaire responders
N = 586 (100.0%)
Individual meeting the 
screening criteria
N = 160 (27.3%)
Individual not meeting screening 
criteria
N = 426 (72.7%)
Diagnostic assessment
N = 130 (22.2%)
Turned down invitation for 
diagnostic assessment
N = 30 (5.1%)
Assessed “False Positive” 
N= 57 (9.7%)
Declined the offer for treatment
N = 15 (2.6%)
Referred to psychiatric 
treatment, N = 40 (6.8%)
Referred to preventive 
treatment, N = 33 (5.6%)
Received psychiatric 
treatment, N = 38 (6.5%)
Received preventive 
treatment, N = 20 (3.4%)
Completed treatment
N = 31 (5.3%)
Completed treatment
N = 17 (2.9%)
Drop-out of treatment
N = 10 (1.7%)
Fig. 2 Screening and identification of clinical and subclinical cases of mental disorders
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Table 2 Sociodemographic characteristics for the study population at initiation of treatment (T1), N (%)
Clinical cases (n = 38) Subclinical cases (n = 20) Untreated cases (n = 15) Healthy subjects (n = 513)
Sex
Female 22 (57.9) 7 (35.0) 11 (73.3) 201 (39.2)
Male 16 (42.1) 13 (65.0) 4 (26.7) 312 (60.8)
Age
Years (mean, sd) 43.6 (9.8) 44.8 (9.3) 46.9 (10.3) 45.3 (9.9)
Marital status
Married/live together 27 (71.1) 15 (75.0) 14 (93.3) 432 (84.2)
Single 11 (28.9) 5 (25.0) 1 (7.1) 81 (15.8)
Company
1: public service 0 (0.0) 6 (30.0) 2 (13.3) 92 (17.9)
2: public service 7 (18.4) 7 (35.0) 1 (6.7) 79 (15.4)
3: private, financial 11 (28.9) 3 (15.0) 6 (40.0) 154 (30.0)
4: private, manufacturing 6 (15.8) 2 (10.0) 1 (6.7) 62 (12.1)
5: private, manufacturing 5 (13.2) 0 (0.0) 2 (13.3) 48 (9.4)
6: public, education 9 (23.7) 2 (10.0) 3 (20.0) 78 (15.2)
Working hour system
Day work 24 (63.2) 17 (85.0) 8 (53.3) 359 (70.0)
Shift work 5 (13.1) 1 (5.0) 3 (20.0) 67 (13.1)
24-h shift 1 (2.6) 1 (5.0) 0 (0.0) 28 (5.5)
Other 8 (21.1) 1 (5.0) 4 (26.7) 59 (11.5)
Field of work
Administration/management 9 (23.7) 5 (25.0) 6 (40.0) 158 (30.8)
Internal logistics and service 13 (34.2) 9 (45.0) 3 (20.0) 136 (26.5)
Teaching 4 (10.5) 2 (10.0) 2 (13.3) 55 (10.7)
Customer service 5 (13.2) 3 (15.0) 0 (0.0) 71 (13.8)
Production 7 (18.4) 0 (0.0) 3 (20.0) 38 (7.4)
Rescue work 0 (0.0) 1 (5.0) 1 (6.7) 50 (9.7)
Other 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4)
N/A 3 (0.6)
Job-satisfaction (mean, sd) 7.3 (2.2) 6.7 (2.2) 7.8 (2.5) 8.6 (1.8)
Length of service
Years (mean, sd) 16.7 (10.6) 17.7 (11.4) 20.9 (12.8) 19.3 (11.6)
Work hours per week
Hours (mean, sd) 35.4 (8.0) 36.6 (4.4) 36.1 (3.0) 37.1 (4.6)
Overtime latest month
Hours (mean, sd) 10.7 (30.9) 4.7 (9.4) 1.9 (4.2) 5.6 (14.7)
Sick days latest month
Days (mean, sd) 4.3 (9.0) 0.2 (0.6) 1.8 (2.3) 0.6 (2.4)
Physical illness
Yes 13 (34.2) 9 (45.0) 7 (46.7) 120 (23.4)
No 25 (65.8) 11 (55.0) 8 (53.3) 393 (76.6)
In treatment with psychotropic drugs
Yes 7 (18.4) 2 (10.0) 3 (20.0) 16 (3.1)
No 31 (81.6) 18 (90.0) 12 (80.0) 497 (96.9)
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might also be connected to the type of treatment. CBT
treatment was considered the best treatment option in
two systematic reviews on preventive interventions for
common mental disorders [23, 27].
Limitations
The findings of this study should be considered with
care. In regard to the analysis of the treatment effect, the
main limitations were the lack of randomisation and the
use of the companies/employees as own controls. Due to
the lack of independent controls, we included the pre-
treatment assessment (T0) in the design as a period for
comparison. Our design therefore introduces definite
possibility for misclassification, but we have no reason to
believe that we have introduced a differential misclassi
fication. However, a non-differential misclassification,
tending to reduce the effect of treatment towards zero,
cannot be excluded.
The lack of control group (randomization) seems to be
a general limitation in workplace directed studies target-
ing mental health problems, which indicates difficulties
in recruiting companies for the sole purpose of being
controls [22]. We estimated that using the companies as
own controls was the best overall design including
ethical issues and real-life circumstances. We experi-
enced, like several other longitudinal studies, a substan-
tial reduction in participation rate. This adds to the
limitations of our findings, most probably by introducing
a non-differential misclassification reducing the odds for
a significant finding of treatment effect.
Table 2 Sociodemographic characteristics for the study population at initiation of treatment (T1), N (%) (Continued)
Clinical cases (n = 38) Subclinical cases (n = 20) Untreated cases (n = 15) Healthy subjects (n = 513)
Season for screening
1. quarter (Jan-Mar) 11 (28.9) 3 (15.0) 6 (40.0) 148 (28.8)
2. quarter (Apr-Jun) 1 (2.6) 0 (0.0) 0 (0.0) 5 (1.0)
3. quarter (Jul-Sep) 22 (57.9) 17 (85.0) 6 (40.0) 300 (58.5)
4. quarter (Oct-Dec) 4 (10.5) 0 (0.0) 3 (20.0) 60 (11.7)
Mean mean score, sd standard deviation
Table 3 Changes on symptomatology during the study period (T0-T3), mean (sd)
Clinical cases
T0 (n = 32) T1 (n = 38) T2 (n = 26) T3 (n = 28) Co-efficient (CI), treatment
period (T1-T3)
p-value
Global Severity Index (GSI) 1.07 (0.49) 1.15 (0.44) 0.94 (0.56) 0.75 (0.67) −0.385 (− 0.576, − 0.194) < 0.001
Subscale – depression (DEP) 1.60 (0.79) 1.74 (0.62) 1.43 (0.88) 1.18 (0.93) −0.574 (− 0.849, − 0.244) 0.004
Subscale – anxiety (ANX) 0.89 (0.72) 0.98 (0.73) 0.78 (0.67) 0.53 (0.73) −0.377 (− 0.561, − 0.193) < 0.001
Subclinical cases
T0 (n = 17) T1 (n = 20) T2 (n = 14) T3 (n = 12) Co-efficient (CI), treatment
period (T1-T3)
p-value
Global Severity Index (GSI) 0.75 (0.48) 0.74 (0.33) 0.46 (0.27) 0.53 (0.36) −0.236 (− 0.457, − 0.016) 0.036
Subscale – depression (DEP) 1.01 (0.75) 1.07 (0.67) 0.75 (0.56) 0.75 (0.55) −0.363 (− 0.748, 0.022) 0.064
Subscale – anxiety (ANX) 0.58 (0.55) 0.52 (0.37) 0.21 (0.21) 0.36 (0.40) −0.220 (− 0.431, − 0.009) 0.041
Untreated cases
T0 (n = 11) T1 (n = 15) T2 (n = 8) T3 (n = 9) Co-efficient (CI), treatment
period (T1-T3)
p-value
Global Severity Index (GSI) 0.73 (0.56) 0.76 (0.39) 0.41 (0.30) 0.49 (0.22) −0.333 (− 0.581, − 0.085) 0.009
Subscale – depression (DEP) 1.06 (0.77) 1.13 (0.57) 0.75 (0.59) 0.88 (0.41) −0.348 (− 0.725, 0.028) 0.070
Subscale – anxiety (ANX) 0.53 (0.51) 0.64 (0.47) 0.29 (0.35) 0.22 (0.16) −0.433 (− 0.708, − 0.159) 0.002
Healthy Subjects
T0 (n = 419) T1 (n = 512) T2 (n = 389) T3 (n = 370) Co-efficient (CI), treatment
period (T1-T3)
p-value
Global Severity Index (GSI) 0.25 (0.27) 0.21 (0.25) 0.19 (0.21) 0.20 (0.25) 0.007 (−0.012, 0.026) 0.472
Subscale – depression (DEP) 0.33 (0.42) 0.27 (0.38) 0.27 (0.35) 0.28 (0.39) 0.027 (−0.005, 0.058) 0.096
Subscale – anxiety (ANX) 0.17 (0.27) 0.14 (0.28) 0.13 (0.24) 0.13 (0.23) 0.001 (−0.022, 0.023) 0.957
Mean mean scale score for each group, sd standard deviation, Co-efficients are reported with confidence intervals (CI)
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The defined control group was composed of a diverse
crowd with somewhat weaker follow-up conditions due
to a shorter pre-assessment period as well as a high
amount of non-responders at follow-up among un-
treated cases. Hence, available data were sparse at
12-month follow-up, leaving the regression line highly
influenced by the data at baseline and at 4- and 6-month
follow-up. Thus, the course of symptoms for the control
group may have been misinterpreted. In addition, the
symptomatic change among all participants might be
effected by regression to the mean as well as seasonal
variations, though these effects have been minimized in
the analysis. Moreover, there is a risk of the results being
biased by internal working conditions, work cultures or
other similarities among workers in specific professions
[45]. We attempted to account for this by including both
private and public companies from diverse line of
business and by including all employees regardless of
education levels. Nonetheless, a non-differential misclas-
sification might have been introduced tending to reduce
the treatment effect to zero.
A major strength of this study was the diverse sample
of Danish employees from different industries and
sectors enhancing the generalisability of the findings.
The study also benefitted from incorporating a long
follow-up period, using validated measures for psycho-
logical distress as well as diagnostic verification of the
self-reported screening results.
Conclusion
In summary, this outreach collaborative model for early
identification seems applicable for identification of both
existing insufficiently treated cases as well as untreated
cases of both clinical and subclinical levels of mental
disorder among a diverse group of Danish employees.
The models’ eligibility are further supported by the
identified high level of unmet need for treatment among
the study sample, which advocates for further develop-
ment of such outreach collaborative models.
Although both treated clinical and subclinical cases
experienced a clinically important improvement in
symptomatic levels, the study did not produce any hard
evidence that this was due to the treatment, primarily
due to weak control conditions. Best valuable evidence
was found for the efficiency of early treatment for
sub-clinical cases. A long-term follow-up in the Danish
national registers on occupational status and health con-
ditions may reveal any difference between treated and
untreated cases in long-term effect of the early identifi-
cation and treatment.
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